Most people aren’t spending their afternoons thinking about the availability of things like kratom, or about 7OH, the kratom compound now sitting squarely in lawmakers’ sights, which is precisely why they think they can get away with using this market as a test case.
Kratom, for those who have never encountered it outside a smoke shop, supplement store, or conversation about alternatives to conventional medicine, is a plant from Southeast Asia that has built a sizeable American following. We’ve written about it previously, here. People buy it in powders, capsules, drinks, and extracts for all sorts of reasons, and whatever one thinks of the product itself (I personally have never tried it), it has existed largely outside the usual pharmacy pipeline.
But 7OH, short for 7-hydroxymitragynine, is now one of the key targets of Georgia’s legislation, and lawmakers are using it as the wedge to drag the wider kratom market into a pharmacist-gated, state-tracked system.
Pulse+ Analysis
Keep reading with Pulse+
This analysis is for Pulse+ members. No billionaires, no corporate cash. Just readers like you.
- Every Pulse+ analysis and investigation, in full
- Ad-free reading across The National Pulse
- Editor’s Notes and members-only comments
First month free · Cancel anytime
Already a member? Sign in
